Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 26, 2009

Simcere Pays $28.5M for Majority Stake in Chinese Vaccine Company

  • Simcere Pharmaceutical plans on acquiring a 37.5% stake in Jiangsu Yanshen Biological Technology for RMB 195.5 million, or about $28.5 million. Upon the closing of the transaction, Simcere is expected to be the largest shareholder in the company.

    Jiangsu Yanshen's core products include an influenza vaccine and a human-use rabies vaccine (vero cell). The products have the second and the fourth largest market shares in China, respectively.

    In addition, Jiangsu Yanshen has received a new medicine certificate from the PRC State Food and Drug Administration for its freeze-dried human-use rabies vaccine (vero cell) and has completed clinical trials of its purified hepatitis A inactivated vaccine (vero cell). GMP certification for the associated new manufacturing facility is pending.

    “Vaccines have strong market potential and represent one of China's key emerging industries,” notes Jinsheng Ren, chairman and CEO of Simcere Pharmaceutical. “We are delighted to enter this new market through our investment in Jiangsu Yanshen.”


    Past News from Simcere

    Simcere Buys 70% Stake in Wuhu Zhong Ren Pharmaceutical for $9.27M (Apr. 22, 2008)

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »